NCT01767441

Brief Summary

Bariatric surgery can lead to improvement or even resolution of type 2 diabetes Mellitus (T2DM) with the spectrum of responses depending also on operation procedures. However, many mechanisms of metabolic action of different surgical techniques still are unclear. The aim of this study is to provide a better understanding of the effects of three types of bariatric surgery (lap banding, gastric bypass and sleeve gastrectomy) on beta-cell function and incretin secretion. A mixed meal tolerance (MMT) test will be performed before and 1 and 12 months after surgery to assess beta cell adequacy and glucagon-like-peptide-1 (GLP1)/glucose-dependent insulinotropic polypeptide (GIP) bioavailability.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 14, 2013

Completed
18 days until next milestone

Study Start

First participant enrolled

February 1, 2013

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

February 24, 2020

Status Verified

August 1, 2012

Enrollment Period

2.8 years

First QC Date

January 11, 2013

Last Update Submit

February 21, 2020

Conditions

Keywords

bariatric surgerygastric bypassgastric bandingsleeve gastrectomyweight lossType 2 Diabetes mellitusGLP1obesitymixed meal test

Outcome Measures

Primary Outcomes (1)

  • change in glucose response (pAUC) to mixed meal test between baseline and 1 month after undergoing bariatric surgery or being put on low calorie diet

    Blood samples will be taken at basal (-20',-10' and 0'), and after the ingestion of a standardized mixed meal (+10', +20', +30',+45', +60', +75', +90', +105', +120', +140', +160', +180', +200', +220', +240', +270', +300').

    1 month

Secondary Outcomes (3)

  • change in glucose response (pAUC) to mixed meal test between baseline and 12 months after undergoing bariatric surgery or being put on low calorie diet

    12 months

  • changes in β-cell response mixed meal test between baseline and 1 and 12 months after undergoing bariatric surgery or being put on low calorie diet

    1 month and 12 months

  • changes in active GLP1 systemic bioavailability during a mixed meal test between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.

    1 month and 12 months

Other Outcomes (1)

  • change in HbA1c between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.

    1 month and 12 months

Study Arms (4)

Roux-en-Y-gastric bypass

morbidly obese subjects undergoing gastric bypass surgery

Procedure: Roux-en-Y-gastric bypass

gastric banding

morbidly obese subjects undergoing laparoscopic adjustable gastric banding

Procedure: laparoscopic adjustable gastric banding

sleeve gastrectomy

morbidly obese subjects undergoing laparoscopic sleeve gastrectomy

Procedure: laparoscopic sleeve gastrectomy

control group

morbidly obese subjects not undergoing bariatric surgery, on diet treatment

Other: diet treatment

Interventions

Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb

Also known as: RYGB
Roux-en-Y-gastric bypass

Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.

Also known as: LAGB
gastric banding

Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His

Also known as: SG
sleeve gastrectomy

Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination

Also known as: diet
control group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

A total of 64 morbidly obese patients will be studied, composed of: * 16 subjects scheduled for Roux-en-Y-gastric bypass; * 16 subjects scheduled for laparoscopic adjustable gastric banding; * 16 subjects scheduled for laparoscopic sleeve gastrectomy; * 16 subjects not undergoing bariatric surgery, on diet treatment (control group)

You may qualify if:

  • BMI \> 40 kg/m2.
  • BMI ≥ 35 kg/m2 and comorbidities.
  • No major organ disease unrelated to excess body weight.
  • Mentally able to understand the study and willingness to participate in the study

You may not qualify if:

  • BMI\< 35 kg/m2.
  • pregnancy/lactation.
  • prior bariatric or gastrointestinal surgery. Malignancies; mental incapacity; unwillingness or language barriers precluding adequate understanding or cooperation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AOUI Verona

Verona, 37126, Italy

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum, plasma

MeSH Terms

Conditions

ObesityWeight LossDiabetes Mellitus, Type 2

Interventions

Gastric BypassDiet

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsBody Weight ChangesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Bariatric SurgeryBariatricsObesity ManagementTherapeuticsGastroenterostomyAnastomosis, SurgicalSurgical Procedures, OperativeDigestive System Surgical ProceduresNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Maria Grazia Zenti, MD

    Division of Endocrinology and Metabolic Diseases, AOUI Verona, Italy

    PRINCIPAL INVESTIGATOR
  • Enzo Bonora, Professor

    Division of Endocrinology and Metabolic Diseases, University Hospital of Verona

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2013

First Posted

January 14, 2013

Study Start

February 1, 2013

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

February 24, 2020

Record last verified: 2012-08

Data Sharing

IPD Sharing
Will not share

Locations